



June 14, 2007

Contact Details:

Email : research@dsl.ie

Tel : +353 1 633 3800
info@dsl.ie Fax : +353 1 677 4708

EQUITIES	Close	Change	% +/-	P/E '07	YTD
ISEQ	9357 ↓	-52	-0.55%	14.1	-0.54%
FTSE 100	6560 ↑	39	0.60%	13.2	5.45%
DAX 30	7681 ↑	3	0.03%	14.2	16.43%
DOW	13482 ↑	187	1.41%	15.2	8.18%
NASDAQ	2582 ↑	33	1.28%	26.1	6.92%
S&P	1516 ↑	23	1.52%	15.9	6.87%

CURRENCIES & RATES	Euro	Dollar	Stg	Yen
Euro	1.0000	1.3308	0.6754	163.4000
Dollar	1.3308	1.0000	1.9703	122.9200
Sterling	0.6754	1.9703	1.0000	241.9800
Interest Rates (%)	3.7500	5.2500	5.5000	0.4800
Oil (Nymex)	66.2600			

This Week's Research
AIB
British Airways
Sterling Energy

Today's Research
Anglo Irish Bank

Today's Recommendation

Anglo (€15.80) Stabilising yields provide entry Stuart Draper
Target : €18 (08/03/07 ; previously €17.50, issued 02/02/07)

- **Bond sell-off** : The stabilisation of long term bond yields within the past 24 hours has created another attractive entry level sub €16 in Anglo Irish Bank. The 10% fall in the Anglo share price over the past 2 weeks was primarily driven by the rise in long term bond yields. However, this process now appears to be stabilising and continued commercial property rental growth provides an important offset to the negative impact on capital values of yields rising further.
- **US expansion** : The latest commercial property investment report from CBRE Richard Ellis also states that it expects investment in commercial property from Irish investors this year to at least match last year's record €11.9 bn, with any supply driven reduction in Ireland being offset by increased investment in the US and Europe, markets where Anglo has been generating strong loan growth in recent years.
- **Loan growth** : Last month, Anglo announced very strong results for the 6 months ended 31/03/07. Profit before tax of €552m was largely in line with the consensus forecast of €552.6m, even though the eps of 60.6c was c.3% ahead of the consensus forecast of 58.7c, largely as a result of a lower tax charge. The results represented spectacular year on year growth of 47% and 45% respectively, even after excluding a €22m profit from the Isle of Man trust sale. The results were driven by very strong 19% (€9.3bn) growth in the loan book over the 6 month period, combined with stable margins and robust credit quality.
- **Attractive upside** : Such continued strong loan growth provides the basis for the consensus current year eps forecast of €1.23, representing 31% growth on the prior year comparative of 93.7c. Such continued stronger than sector average earnings growth warrants a premium rating of c.20%, and as a result our current 12 month price target of €18 (14% upside) is based on 12x consensus eps of €1.48 for the year ending 30/09/08. Given the size of the bank's growth opportunity in both the UK and US markets, sustainable average earnings growth of 15% per annum appears achievable over the next 5 years, significantly stronger than the European bank sector average as a result of Anglo's unique niche business model. Such sustainably strong growth means that Anglo deserves such a premium rating : **BUY**.

Breaking News

Barclays to consider sweetening ABN bid

Barclays has drawn up contingency plans to restructure its all-share offer for ABN Amro with a significant cash sweetener in case it is forced into a full-blown battle for control of the Dutch lender. Barclays realises that, unless legal disputes run in its favour, it will need to improve its €65bn offer if it is to trump the RBS-led consortium. But it is mindful of warnings from shareholders not to raise its price. It is therefore looking at reducing the number of shares it would issue for ABN Amro and replacing them with cash. Barclays is not expected to make a decision about restructuring its offer until it becomes clear whether the RBS-led consortium can press ahead with its rival €71.4bn break-up bid for ABN Amro.

GSK facing pressure to sell Consumer Healthcare Unit

GlaxoSmithKline is facing mounting pressure from shareholders to sell its over-the-counter medicines business. Analysts believe the business, which makes brands such as Ribena, Lucozade and Panadol, could fetch between £9bn and £12bn. Investors are unhappy with the lack of progress in the group's share price, which is trading at early 2005 levels having fallen 10% since May, in the midst of a safety scare around diabetes drug Avandia. The paper cited one shareholder as saying the group is 'wide open' to receive a letter similar to that sent to Vodafone last week by a hedge fund, calling for greater returns to investors.

AIWS announce completion of a €450m private placing

IAWS announced Today the completion of a \$450m Guaranteed Senior Note Private Placement with US and UK institutions. The notes were issued on June 13, 2007 with a weighted average tenor of over 9.2 years. They were placed at a weighted average rate of 5.82% based on US Treasury with interest payable semi-annually. The proceeds of the placement will re-finance and lengthen the maturity profile of portion of the Group's existing borrowing facilities. Patrick McEniff, Finance Director, said: "The combined impact of placing long term debt and the releasing of approx. €265m in cash from Origin has considerably strengthened the IAWS balance sheet."

Business Press

- IN&M says O'Brien claims 'outrageous' (IT)
- Businesses positive about Irish Economy (IT)
- Greencore shares up on bid speculation (IE)
- Deadline extended for ICG offers (IE)

Investment Press

Commodities/rates: Inflation scare? What inflation scare? The sovereign bond sell off might have spooked equities investors but commodities markets have shown less concern.

Disclaimer: The information in this document has been obtained from sources, which we believe to be reliable. We cannot guarantee its accuracy or completeness. It does not constitute a solicitation for the purchase or sale of any investment. Any person acting on the information contained in this document does so at their own risk. Recommendations in this document may not be suitable for all investors. Individual circumstances should be considered before a decision to invest is taken. Investors should note the following: Past experience is not necessarily a guide to future performance. The value of investments may fall or rise against investors' interests. Income levels from investments may fluctuate. Changes in exchange rates may have an adverse effect on the value of, or income from, investments denominated in foreign currencies. Dolmen Securities is a Member Firm of the London Stock Exchange, and is authorised by the Financial Regulator under the Investment Intermediaries Act 1995. Dolmen Stockbrokers is a Member Firm of The Irish Stock Exchange, The London Stock Exchange, and is authorised by the Financial Regulator under the Stock Exchange Act 1995.

DOLMEN SECURITIES → Website : www.dolmenstockbrokers.ie
 75 St. Stephen's Green, Dublin 2, Ireland.
 45 South Mall, Cork, Ireland.
 Theatre Court, Mallow Street, Limerick, Ireland

• Tel : +353 1 633 3800
 • Tel : +353 21 422 2122
 • Tel : +353 61 436 500

• Fax : +353 1 677 7044
 • Fax : +353 21 422 2123
 • Fax : +353 61 436 599

• Email : info@dsl.ie
 • Email : cork@dsl.ie
 • Email : limerick@dsl.ie



Disclosures

This report has been prepared by Dolmen Stockbrokers ('Dolmen') for information purposes only to assist investors to make their own investment decisions and is not intended to and does not constitute personal recommendations nor provide the sole basis for any evaluation of the securities discussed. Specifically the information contained in this report should not be taken as an offer or solicitation of investment advice or, encourage the purchase or sale of any particular security, option, future or other derivative investment. Not all recommendations are necessarily suitable for all investors and Dolmen recommend that specific advice should always be sought prior to investment, based on the particular circumstances of the investor.

Although the information in this report has been obtained from sources, which Dolmen believes to be reliable and all reasonable efforts are made to present accurate information Dolmen give no warranty or guarantee as to, and do not accept responsibility for, the correctness, completeness, timeliness or accuracy of the information provided or its transmission. Nor shall Dolmen, or any of its employees, directors or agents, be liable to for any losses, damages, costs, claims, demands or expenses of any kind whatsoever, whether direct or indirect, suffered or incurred in consequence of any use of, or reliance upon, the information. Any person acting on the information contained in this report does so entirely at his or her own risk.

All estimates, views and opinions included in this report constitute Dolmen's judgement as of the date of the report but may be subject to change without notice. Changes to assumptions may have a material impact on any recommendations made herein.

Unless specifically indicated to the contrary this report has not been disclosed to the covered issuers(s) in advance of publication.

Past performance is not necessarily a guide to future returns. The value of investments and the income from them can fall as well as rise. Investments denominated in foreign currencies are subject to fluctuations in exchange rates, which may have an adverse affect on the value of the investments, sale proceeds, and on dividend or interest income. Investors may not necessarily recoup the full value of their original investment. Investors should be aware that forwarding looking statements and forecasts may not be realised.

This report may not be reproduced (in whole or in part) altered, transmitted or made available to any other person without the prior written permission of Dolmen.

Dolmen Securities is a Member Firm of the London Stock Exchange, and is authorised by the Financial Regulator under the Investment Intermediaries Act 1995. Dolmen Stockbrokers is a Member Firm of The Irish Stock Exchange, The London Stock Exchange, and is authorised by the Financial Regulator under the Stock Exchange Act 1995.

Conflicts of Interest & Share Ownership Policy

Dolmen, its employees, directors or related companies, may have a shareholding in the securities (or related investments/ derivatives) of certain companies covered in this report, or may provide/ solicit investment banking or other services to/ from them.

It is noted that research analysts' compensation is impacted upon by overall firm profitability and accordingly may be affected to some extent by revenues arising other Dolmen business units including Corporate Finance, Fund Management and Stockbroking. Revenues in these business units may derive in part from the recommendations or views in this report. Notwithstanding, Dolmen is satisfied that the objectivity of views and recommendations contained in this report has not been compromised.

Dolmen permits research analysts to own shares and/ or derivative positions in issuers they publish research, views and recommendations on and accordingly analysts involved in the production of this report may own stocks in a company covered in it. Any own account staff trading is undertaken in strict compliance with Dolmen's own account internal rules and therefore Dolmen is satisfied that the impartiality of research, views and recommendations remains assured.

Analyst Certification

Each research analyst responsible for the content of this report, in whole or in part, certifies that: (1) all of the views expressed accurately reflect his or her personal views about those securities or issuers; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in the research report. Stuart Draper and Stephen Taylor are responsible for the production of this report. Stuart Draper is Head of Research and Stephen Taylor is an equity analyst.

For US Persons Only

This report is only provided in the US to major institutional investors as defined by s. 15 a-6 of the Securities Exchange Act, 1934 as amended. A US recipient of this report shall not distribute or provide this report or any part thereof to any other person.